NCT05394116: An ongoing trial by Regeneron Pharmaceuticals
This trial is ongoing. It must report results 7 months from now.
Full data
| Full entry on ClinicalTrials.gov | NCT05394116 |
|---|---|
| Title | Phase 3 Randomized, Placebo-Controlled Study to Assess Safety, Tolerability, and Efficacy of Garetosmab in Patients With Fibrodysplasia Ossificans Progressiva |
| Results Status | Ongoing |
| ACT or pACT? | This is what FDAAA officially calls an "Applicable Clinical Trial" |
| Start date | Nov. 21, 2022 |
| Completion date | July 17, 2025 |
| Required reporting date | July 17, 2026, midnight |
| Actual reporting date | None |
| Date last checked at ClinicalTrials.gov | Dec. 12, 2025 |
| Days late | None |